Osimertinib and Performance Status 2: Not Every Patient Fits Into a Pivotal Clinical Trial

This publication has 7 references indexed in Scilit:

• A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040)
  Journal of Thoracic Oncology, 2025
• Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
  Annals of Oncology, 2023
• Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2018
• A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
  Journal of Thoracic Oncology, 2014
• Survival among non-small cell lung cancer patients with poor performance status after first line chemotherapy
  Lung Cancer, 2012
• Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.
  Journal of Clinical Oncology, 1991
• Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide
  Journal of Chronic Diseases, 1960